The Group has formulated new long-term management goals for fiscal year ending March 31, 2033.

To achieve our vision of becoming No.1 in Asia, we will strengthen our competitiveness by harnessing our strengths such as reliability, customer responsiveness, and stable quality, strengthening our sales capabilities in overseas markets, expanding our supply capacity, and leveraging alliances.

[Management Targets]

We aim for unprecedented dramatic growth with net sales of ¥80.0 billion and operating income of ¥10.0 billion in the fiscal year ending March 31, 2033.

[Ideal Vision]

・Regional portfolio: We will expand sales to overseas markets where growth is particularly expected, and significantly increase the proportion of Asia, including India.
・Product portfolio: Our growth pillars will be gelatin and collagen peptides, which are expected to continue to grow. In addition, we will significantly grow biomedical and new businesses.
 

[Cash Allocation]

・In order to fulfill our growth strategy, we will significantly expand strategic investments, primarily to expand supply capacity for faster paced globalization.
・With regard to shareholder returns, we will raise DOE* from 2.0%, which is the target in the current Medium-Term Management Plan, to 4.0% by the fiscal year ending March 31, 2033.
* DOE: Divided on equity
 

As for the profit target for the final year of the Medium-Term Management Plan (April 1, 2024–March 31, 2027) announced on May 15, 2024, we have revised the operating income target upward from ¥3.5 billion to ¥4.5 billion because the operating income forecast for the fiscal 2026 (ending March 31, 2026) exceeds the initial target.
In addition, we changed the dividend target for the final fiscal year from DOE of 2.0% to 3.0%